In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating and $105.00 price target on Pacira Pharmaceuticals PCRX.
In the report, Bank of America noted, “PCRX CFO Jim Scibetta led a tour yesterday of the company's San Diego-based manufacturing facility, which will soon have $400mn in production sales capacity, post the near-term approval of the second train in Suite C. Debottlenecking and cycle time reductions for both Suite A and C may have effectively added significant upside to this nameplate capacity.. The next tranche of capacity will come from a Suite C-like expansion at Patheon's facility in the UK, which is expected to be on stream in 2H16. A second suite at Patheon is being developed with 2x the capacity of Suite C. PCRX also has a fully functional pilot unit for the new continuous spray process, which is expected to have 3x the throughput of the existing process (e.g. $1bn in revenue capacity for a Suite C size process). Consistent with our prior view, Exparel's long-term revenue potential will not be manufacturing limited.”
Pacira Pharmaceuticals closed on Tuesday at $97.55.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in